Nektar Therapeutics (NKTR) Highlights Data from First-in-Human Phase 1a Study on Novel T Regulatory Cell Stimulator, NKTR-358
Go back to Nektar Therapeutics (NKTR) Highlights Data from First-in-Human Phase 1a Study on Novel T Regulatory Cell Stimulator, NKTR-358| Nektar Therapeutics (NASDAQ: NKTR) | Delayed: 73.15 +2.11 (2.97%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $71.04 | 52 Week High | $19.98 | |||
| Open | $70.05 | 52 Week Low | $10.52 | |||
| Day High | $74.79 | P/E | N/A | |||
| Day Low | $69.00 | EPS | $-1.45 | |||
| Volume | 1,086,680 | |||||
